Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$96.48
2.112.24%
al cierre: Nov 17, 4:00 PM EST
$96.00
-0.48-0.50%
After hour: 5:12 PM EST
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Guardant Health Inc tiene un precio objetivo de consenso de $66.77 basado en las calificaciones de 32 analistas. El máximo es $110, emitido por UBS el octubre 30, 2025. El mínimo es $32, emitido por Jefferies el junio 3, 2024. Las 3 calificaciones de analistas más recientes fueron publicadas por UBS, Citigroup y Evercore ISI Group el octubre 30, 2025, respectivamente. Con un precio objetivo promedio de $100 entre UBS, Citigroup y Evercore ISI Group, hay una 4.17% upside implícita para Guardant Health Inc según estas calificaciones más recientes de analistas.
Firmas de analistas que realizan recomendaciones1
UBS
Citigroup
Evercore ISI Group
Barclays
Canaccord Genuity
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Guardant Health
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/30/2025 | 14.58% | UBS | $80 → $110 | Maintains | Buy | |||
10/30/2025 | 4.17% | Citigroup | $65 → $100 | Maintains | Buy | |||
10/30/2025 | -6.25% | Evercore ISI Group | $68 → $90 | Maintains | Outperform | |||
10/30/2025 | -11.46% | Barclays | $70 → $85 | Maintains | Overweight | |||
10/30/2025 | 4.17% | Canaccord Genuity | $75 → $100 | Maintains | Buy | |||
10/30/2025 | 4.17% | BTIG | $80 → $100 | Maintains | Buy | |||
10/22/2025 | -6.25% | Piper Sandler | $60 → $90 | Maintains | Overweight | |||
10/07/2025 | -29.17% | Evercore ISI Group | $60 → $68 | Maintains | Outperform | |||
10/02/2025 | -27.08% | Barclays | $60 → $70 | Maintains | Overweight | |||
09/26/2025 | -21.88% | Canaccord Genuity | $65 → $75 | Maintains | Buy | |||
09/25/2025 | -25% | TD Cowen | $63 → $72 | Maintains | Buy | |||
09/25/2025 | -27.08% | Stifel | $60 → $70 | Maintains | Buy | |||
09/25/2025 | -21.88% | Leerink Partners | $70 → $75 | Maintains | Outperform | |||
09/25/2025 | -27.08% | Mizuho | $65 → $70 | Maintains | Outperform | |||
09/25/2025 | -21.88% | Wolfe Research | → $75 | Upgrade | Peer Perform → Outperform | |||
09/25/2025 | -16.67% | UBS | $70 → $80 | Maintains | Buy | |||
09/25/2025 | -30.21% | Guggenheim | $56 → $67 | Maintains | Buy | |||
09/25/2025 | -27.08% | JP Morgan | $60 → $70 | Maintains | Overweight | |||
09/25/2025 | -16.67% | BTIG | $70 → $80 | Maintains | Buy | |||
09/22/2025 | -25% | Wells Fargo | → $72 | Initiates | → Overweight | |||
09/22/2025 | -27.08% | BTIG | $70 → $70 | Reiterates | Buy → Buy | |||
09/04/2025 | -27.08% | BTIG | $65 → $70 | Maintains | Buy | |||
07/31/2025 | -37.5% | Scotiabank | $57 → $60 | Maintains | Sector Outperform | |||
07/31/2025 | -36.46% | Raymond James | $59 → $61 | Maintains | Outperform | |||
06/13/2025 | -32.29% | Mizuho | $60 → $65 | Maintains | Outperform | |||
05/06/2025 | -37.5% | Piper Sandler | $50 → $60 | Maintains | Overweight | |||
05/05/2025 | -40.63% | Scotiabank | $52 → $57 | Maintains | Sector Outperform | |||
05/01/2025 | -32.29% | Canaccord Genuity | $60 → $65 | Maintains | Buy | |||
05/01/2025 | -37.5% | Stifel | $53 → $60 | Maintains | Buy | |||
05/01/2025 | -37.5% | Barclays | $55 → $60 | Maintains | Overweight | |||
05/01/2025 | -37.5% | TD Securities | $56 → $60 | Maintains | Buy | |||
05/01/2025 | -27.08% | UBS | $65 → $70 | Maintains | Buy | |||
04/10/2025 | -42.71% | Barclays | $60 → $55 | Maintains | Overweight | |||
04/10/2025 | -42.71% | Mizuho | → $55 | Initiates | → Outperform | |||
03/26/2025 | -42.71% | Stephens & Co. | $55 → $55 | Reiterates | Overweight → Overweight | |||
03/06/2025 | -45.83% | Morgan Stanley | $42 → $52 | Maintains | Overweight | |||
02/26/2025 | -47.92% | Piper Sandler | $34 → $50 | Maintains | Overweight | |||
02/24/2025 | -41.67% | Guggenheim | $56 → $56 | Reiterates | Buy → Buy | |||
02/24/2025 | -45.83% | Scotiabank | $47 → $52 | Maintains | Sector Outperform | |||
02/24/2025 | -37.5% | Canaccord Genuity | $42 → $60 | Maintains | Buy | |||
02/21/2025 | -41.67% | Goldman Sachs | $49 → $56 | Maintains | Buy | |||
02/21/2025 | -38.54% | Raymond James | $39 → $59 | Reiterates | Outperform → Outperform | |||
02/21/2025 | -42.71% | JP Morgan | $50 → $55 | Maintains | Overweight | |||
02/21/2025 | -44.79% | Stifel | $45 → $53 | Maintains | Buy | |||
01/28/2025 | -48.96% | Goldman Sachs | $36 → $49 | Maintains | Buy | |||
01/23/2025 | -37.5% | Barclays | → $60 | Initiates | → Overweight | |||
01/22/2025 | — | Guggenheim | — | Reiterates | Buy → Buy | |||
11/07/2024 | -47.92% | JP Morgan | $48 → $50 | Maintains | Overweight | |||
11/07/2024 | -62.5% | Goldman Sachs | $32 → $36 | Maintains | Buy | |||
10/30/2024 | -63.54% | Bernstein | $40 → $35 | Maintains | Outperform | |||
10/17/2024 | -47.92% | Leerink Partners | — | $60 → $50 | Maintains | Outperform | ||
08/21/2024 | -58.33% | UBS | $32 → $40 | Maintains | Buy | |||
08/13/2024 | -64.58% | Piper Sandler | $30 → $34 | Maintains | Overweight | |||
08/08/2024 | -53.13% | Citigroup | $40 → $45 | Maintains | Buy | |||
08/08/2024 | -56.25% | TD Cowen | $41 → $42 | Maintains | Buy | |||
08/08/2024 | -61.46% | Craig-Hallum | $28 → $37 | Maintains | Buy | |||
08/08/2024 | -50% | JP Morgan | $45 → $48 | Maintains | Overweight | |||
07/30/2024 | -47.92% | BTIG | $45 → $50 | Maintains | Buy | |||
07/29/2024 | -56.25% | Canaccord Genuity | $38 → $42 | Maintains | Buy | |||
07/18/2024 | -58.33% | B of A Securities | $28 → $40 | Maintains | Buy | |||
07/17/2024 | -66.67% | Goldman Sachs | $28 → $32 | Maintains | Buy | |||
06/28/2024 | -62.5% | Guggenheim | → $36 | Upgrade | Neutral → Buy | |||
06/04/2024 | -60.42% | Canaccord Genuity | $30 → $38 | Maintains | Buy | |||
06/03/2024 | -66.67% | Jefferies | → $32 | Initiates | → Buy | |||
05/24/2024 | -54.17% | Stephens & Co. | $44 → $44 | Reiterates | Overweight → Overweight | |||
04/29/2024 | -68.75% | Canaccord Genuity | $45 → $30 | Maintains | Buy | |||
04/24/2024 | -70.83% | Craig-Hallum | → $28 | Assumes | → Buy | |||
04/15/2024 | -70.83% | Goldman Sachs | $32 → $28 | Maintains | Buy | |||
04/05/2024 | — | Guggenheim | — | Reiterates | → Neutral | |||
02/26/2024 | -68.75% | Piper Sandler | $40 → $30 | Maintains | Overweight | |||
02/23/2024 | -53.13% | JP Morgan | $60 → $45 | Maintains | Overweight | |||
02/23/2024 | -53.13% | Canaccord Genuity | $50 → $45 | Maintains | Buy | |||
01/30/2024 | -61.46% | Goldman Sachs | $43 → $37 | Maintains | Buy | |||
01/29/2024 | -61.46% | Goldman Sachs | $43 → $37 | Maintains | Buy | |||
12/14/2023 | — | Guggenheim | — | Initiates | → Neutral | |||
12/13/2023 | — | Wolfe Research | — | Initiates | → Peer Perform | |||
11/13/2023 | -71.88% | Raymond James | → $27 | Upgrade | Market Perform → Outperform | |||
11/08/2023 | -47.92% | Morgan Stanley | $55 → $50 | Maintains | Overweight | |||
10/23/2023 | -53.13% | Goldman Sachs | $52 → $45 | Maintains | Buy | |||
10/20/2023 | -53.13% | Goldman Sachs | $52 → $45 | Maintains | Buy | |||
10/02/2023 | -47.92% | Citigroup | $50 → $50 | Reiterates | Buy → Buy | |||
09/28/2023 | -64.58% | Bernstein | → $34 | Initiates | → Outperform | |||
09/27/2023 | -58.33% | Piper Sandler | → $40 | Upgrade | Neutral → Overweight | |||
08/08/2023 | -58.33% | Piper Sandler | $30 → $40 | Maintains | Neutral | |||
08/07/2023 | -42.71% | Morgan Stanley | $60 → $55 | Maintains | Overweight | |||
08/04/2023 | -47.92% | Citigroup | $40 → $50 | Maintains | Buy | |||
05/26/2023 | -58.33% | Citigroup | → $40 | Upgrade | Neutral → Buy | |||
05/11/2023 | -37.5% | Morgan Stanley | $66 → $60 | Maintains | Overweight | |||
05/10/2023 | -42.71% | Credit Suisse | $60 → $55 | Maintains | Outperform | |||
05/01/2023 | — | OTR Global | — | — | Downgrade | Mixed → Negative | ||
03/09/2023 | -65.63% | Citigroup | $60 → $33 | Downgrade | Buy → Neutral | |||
03/03/2023 | -63.54% | Piper Sandler | $50 → $35 | Maintains | Neutral | |||
02/27/2023 | -31.25% | Morgan Stanley | $73 → $66 | Maintains | Overweight | |||
02/24/2023 | -47.92% | BTIG | $60 → $50 | Maintains | Buy | |||
02/24/2023 | -37.5% | Canaccord Genuity | $65 → $60 | Maintains | Buy | |||
02/24/2023 | -44.79% | Cowen & Co. | $70 → $53 | Maintains | Outperform | |||
02/24/2023 | -32.29% | JP Morgan | $75 → $65 | Maintains | Overweight | |||
02/24/2023 | -37.5% | Credit Suisse | $70 → $60 | Maintains | Outperform | |||
02/21/2023 | -23.96% | Morgan Stanley | $80 → $73 | Maintains | Overweight | |||
02/16/2023 | -34.38% | Stephens & Co. | → $63 | Reiterates | → Overweight |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Guardant Health (GH)?
El último precio objetivo de Guardant Health (NASDAQ:GH) fue comunicado por UBS el octubre 30, 2025. La firma de analistas fijó un precio objetivo para $110.00 que espera GH a rise dentro de 12 meses (un posible 14.58% upside). 47 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Guardant Health (GH)?
La última calificación de analistas para Guardant Health (NASDAQ:GH) fue proporcionada por UBS, y Guardant Health mantuvo su buy calificación.
¿Cuándo se produjo la última revisión al alza de Guardant Health (GH)?
La última revisión al alza de Guardant Health Inc se produjo en septiembre 25, 2025, cuando Wolfe Research elevó su precio objetivo a $75. Wolfe Research anteriormente tenía a peer perform para Guardant Health Inc.
¿Cuándo fue la última revisión a la baja de Guardant Health (GH)?
La última revisión a la baja de Guardant Health Inc se produjo en mayo 1, 2023, cuando OTR Global cambió su precio objetivo de N/A a N/A para Guardant Health Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Guardant Health (GH)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Guardant Health, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Guardant Health se registró el octubre 30, 2025, por lo que la próxima calificación estará disponible en torno al octubre 30, 2026.
¿Es correcta la calificación de los analistas sobre Guardant Health (GH)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Guardant Health (GH) fue un mantuvo con un precio objetivo de $80.00 a $110.00. El precio actual al que cotiza Guardant Health (GH) es de $96.00, que es within del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.